MHC-I binding
peptides and
beta 2 microglobulin (beta 2-m) can upregulate the MHC-I heavy chain expression on certain
peptide transporter mutant cells. We have further studied this with normal cells and non-mutant cell lines. No MHC-I upregulation was seen with normal, resting or activated T cells. On mouse cell lines P815 and B16, both
peptides and human beta 2-m gave an additive upregulation response. With the human
small cell lung carcinoma H82, an optimal HLA.A2 binding
peptide (
GILGFVFTL) gave an upregulation response, whereas beta 2-m alone or in combination with this
peptide had no effect. However, beta 2-m potentiated the response of H82 cells to a slightly longer
peptide. Using mutant RMA-S cells, it was found that both
Brefeldin A (BFA) and
chloroquine, but not
leupeptin, inhibited MHC-I upregulation response to both
peptide and beta 2-m. In contrast to
chloroquine, BFA also gave a reduction of background membrane MHC-I expression, presumably due to a block in Golgi transport. Human beta 2-m, which binds to RMA-S cells, and which is known to internalize into endosomes, did not reappear on the cell surface. When Db on RMA-S cells was upregulated by human beta 2-m, the sensitivity of these cells to Db restricted CTL cells increased. Even if beta 2-m did not upregulate the overall MHC-I expression on normal cells, it may still quantitatively increase the expression of optimally presented
peptides and endosomal recycling many be important in this process.